RM-MET / Metabolic and incretin signalling
Linaclotide
Also known as: MD-1100 · Guanylate cyclase-C agonist peptide
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Linaclotide is a compact disulfide-rich peptide that acts at guanylate cyclase-C. The labeled evidence concerns an oral capsule presentation and should not be transferred to other forms.
Evidence position
An FDA-labeled comparator and randomized trials support Grade A for the regulated product.
What the record does not establish
Those records do not authenticate loose peptide, a different route or a third-party sample.
Sources
- 01Linzess prescribing informationDailyMed / U.S. National Library of Medicine
- Shows
- Current U.S. label for a defined oral capsule product
- Does not show
- Does not describe loose peptide or another formulation
- 02Linaclotide 26-week randomized controlled trialPubMed
- Shows
- Randomized human evidence for the finished oral presentation
- Does not show
- Does not verify another material or route
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Linaclotide
- CID
- 16158208
- Formula
- C59H79N15O21S6
- Mass
- 1526.8
PUBMED / FOUND RECORDS
- Irritable bowel syndrome.Medicina clinica / 2022 Jan 21PMID 34238582 / DOI 10.1016/j.medcli.2021.04.029
- American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.Gastroenterology / 2023 JunPMID 37211380 / DOI 10.1053/j.gastro.2023.03.214
- Management of Chronic Constipation: A Comprehensive Review.Internal medicine (Tokyo, Japan) / 2025 Jan 1PMID 37952945 / DOI 10.2169/internalmedicine.2867-23
- Linaclotide. / 2006PMID 29999932
- Management of Constipation in Older Adults.American family physician / 2015 Sep 15PMID 26371734
CLINICALTRIALS.GOV / FOUND RECORDS
- A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional ConstipationCOMPLETED / PHASE3 / AbbVieNCT05652205 / DIRECT intervention MATCH: Linaclotide
- Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)COMPLETED / NO PHASE / Astellas Pharma IncNCT03471728 / DIRECT intervention MATCH: Linaclotide
- Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)COMPLETED / PHASE2 / Ironwood Pharmaceuticals, Inc.NCT02559206 / DIRECT intervention MATCH: Linaclotide
- Clinical Study of Bowel Preparation Before ColonoscopyCOMPLETED / NA / Jinling Hospital, ChinaNCT06091735 / DIRECT intervention MATCH: Linaclotide
- Linaclotide Acetate in Preventing Colorectal Cancer in Healthy VolunteersCOMPLETED / PHASE1 / Mayo ClinicNCT01950403 / DIRECT intervention MATCH: Linaclotide